
COGT Stock Forecast & Price Target
COGT Analyst Ratings
Bulls say
Cogent Biosciences is a biotechnology company with a promising pipeline of precision therapies for genetically defined diseases, including its lead program CGT9486 targeting KIT D816V and other mutations in Systemic Mastocytosis and GIST. With a projected market value of $9.4B based on a discounted cash flow analysis and strong cash position, the company is poised for success pending FDA approvals and positive clinical data. Risks include setbacks in clinical trials and regulatory approval, but the potential for commercial success and pipeline expansion make COGT a compelling investment opportunity.
Bears say
Cogent Biosciences is facing significant risks in achieving their price target and rating, as clinical results from their key CGT9486 program may lead to downward adjustments in market penetration, higher discount rates, and a longer horizon to approval. However, their recent FDA acceptance and priority review for bezuclastinib in combination with sunitinib for previously treated GIST patients is a positive sign, with potential approval likely based on positive Phase 3 PEAK data. Additionally, the company's potential launches in GIST and indolent systemic mastocytosis could lead to significant revenue growth, but the outcome of upcoming regulatory and clinical catalysts remains uncertain.
This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.
COGT Analyst Forecast & Price Prediction
Start investing in COGT
Order type
Buy in
Order amount
Est. shares
0 shares